All In Biotech

Drug Trial Radar · NCT04421495

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China

Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China

Last checked: Nov 19, 2026Latest source record: Jul 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

608

Actual

Start

Jul 16, 2020

Primary completion

Jun 16, 2022

Study completion Jul 16, 2024

Sponsor

Lead sponsor
Beijing Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.

Conditions

  • Multidrug Resistant Tuberculosis

Interventions

  • DelamanidDrug

    the eligible patients will be give damanid-containing regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants experiencing all-cause mortalityTime frame: from enrollment to the completion of the trial ,an average of 30-32months
  2. Proportion of participants experiencing treatment-emergent AEsTime frame: the whole treatment phase,an average of 18-20 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China

  • Changsha Central Hospital

    Changsha, China

  • Public Health Clinical Center of Chengdu

    Chengdu, China

  • Chongqing Infectious Disease Medical Center

    Chongqing, China

  • Fuzhou Pulmonary Hospital of Fujian

    Fuzhou, China

  • Guangzhou Chest Hospital

    Guangzhou, China

  • Guiyang Public Health Clinical Center

    Guiyang, China

  • Heilongjiang Province center for tuberculosis Control and Prevention

    Haerbin, China

  • Hangzhou Red Cross Hospital

    Hangzhou, China

  • Jiamusi Tumor Hospital

    Jiamusi, China

  • Tuberculosis Hospital in Jilin Province

    Jilin City, China

  • Shandong Provincial Chest Hospital

    Jinan, China

  • The Third People's Hospital of Kunming City

    Kunming, China

  • Lanzhou Pulmonary Hospital

    Lanzhou, China

  • Longtan Hospital of Guangxi Zhuang Autonomous Region

    Liuzhou, China

  • Jiangxi Chest (Third People) Hospital

    Nanchang, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Hebei Chest Hospital

    Shijiangzhuang, China

  • The Fifth People Hospital of Suzhou

    Suzhou, China

  • The Fourth People's Hospital of Taiyuan

    Taiyuan, China

  • Wuhan Institute For Tuberculosis Control

    Wuhan, China

  • Wuhan Jinyintan Hospital

    Wuhan, China

  • Shanxi Provincial Tuberculosis Institute

    Xi'an, China

  • Xi'an Chest Hospital

    Xi'an, China

  • Henan Provincial Chest Hospital

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.